Status:
COMPLETED
Women's Assessed Cardiovascular Evaluation With MCG
Lead Sponsor:
Genetesis Inc.
Conditions:
Ischemia
Cardiac Disease
Eligibility:
FEMALE
18+ years
Brief Summary
Cardiovascular disease (CVD) is the number one cause of death for women over the age of 25, accounting for 1 of every 3 female deaths. Research has shown that while hypertension in women is less contr...
Eligibility Criteria
Inclusion
- ≥ 18 years of age at the time of enrollment. Female Patients deemed at risk for cardiovascular disease (breast cancer survivors, patients referred to cardiologists, prior COVID-19 patients, etc.)
Exclusion
- \< 18 years of age Patients unable to fit into device Non-ambulatory patients Positive response on CardioFlux Pre-Screening Form Patients with claustrophobia or unable to lie supine for 5 minutes Pregnant women Poor candidate for follow-up (e.g. no access to phone) Prisoners
Key Trial Info
Start Date :
October 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 21 2022
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT04739280
Start Date
October 15 2020
End Date
July 21 2022
Last Update
February 23 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Genetesis Facility
Mason, Ohio, United States, 45040